Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 28.04 B
The data is delayed by 15 minutes.
ALXN is in the long-term up 2384% in 26 years.
Description: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is
|Shares Outstanding||224.02 M||EPS||3.07||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||17.14%||Sales Growth - Q/Q||0.14%||P/E||37.13|
|P/E To EPS Growth||P/S||12.36||P/BV||7.97||Price/Cash Per Share||14.56|
|Price/Free Cash Flow||55.69||ROA||13.34%||ROE||16.74%||ROI||15.36%|
|Current Ratio||4.92||Quick Ratio||4.61||Long Term Debt/Equity||0.05||Debt Ratio||0.17|
|Gross Margin||90.72%||Operating Margin||33.65%||Net Profit Margin||25.97%||Dividend Payout Ratio|
|Cash From Financing Activities||5.07 M||Cash From Investing Activities||-48.42 M||Cash From Operating Activities||23.03 M||Gross Profit||584.2 M|
|Net Profit||170.22 M||Operating Profit||181.08 M||Total Assets||13.17 B||Total Current Assets||2.53 B|
|Total Current Liabilities||769.17 M||Total Debt||3.5 B||Total Liabilities||4.61 B||Total Revenue||636.21 M|
|High 52 week||141.3||Low 52 week||93.94||Last close||130.9||Last change||-0.38%|
|RSI||41.11||Average true range||3.76||Beta||1.14||Volume||2.37 M|
|Simple moving average 20 days||-1.22%||Simple moving average 50 days||-2.32%||Simple moving average 200 days||5.77%|
|Performance Week||-0.6%||Performance Month||3.96%||Performance Quart||1.14%||Performance Half||10.45%|
|Performance Year||9.39%||Performance Year-to-date||34.45%||Volatility daily||1.92%||Volatility weekly||4.28%|
|Volatility monthly||8.78%||Volatility yearly||30.41%||Relative Volume||244.27%||Average Volume||1.33 M|
|New High||New Low|
2019-11-12 11:37:00 | Buy Big Biotech — But Not Gilead, Analyst Says
2019-11-11 12:51:49 | Drugmaker Amgen cuts a quarter of its Kendall Square research staff
2019-11-11 09:15:02 | Celgene CELG Hits 52-Week High, Can the Run Continue?
2019-11-08 08:00:01 | Pharma Sector Tops in October: Best ETFs & Stocks
2019-11-04 17:05:10 | Biotech ETFs in Focus on Impressive Q3 Earnings Results
2019-11-01 09:30:01 | Has Alexion Pharmaceuticals ALXN Outpaced Other Medical Stocks This Year?
2019-10-31 11:36:03 | The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG
2019-10-31 09:30:01 | ALXN or CBM: Which Is the Better Value Stock Right Now?
2019-10-31 06:52:10 | Try Rising P/E Investing With 5 Top-Ranked Stocks
2019-10-31 06:30:00 | Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B
2019-10-30 10:56:02 | Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
2019-10-30 10:43:57 | Healthcare ETFs Win in October: Here's Why
2019-10-29 08:45:12 | Here is Why Growth Investors Should Buy Alexion ALXN Now
2019-10-28 11:59:03 | Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
2019-10-28 11:18:33 | 3 ‘Perfect 10’ Biotech Stocks to Buy Amid Volatile Market Environment
2019-10-25 09:37:05 | 3 ‘Strong Buy’ Stocks Top Investors Are Buying
2019-10-24 09:31:01 | Company News For Oct 24, 2019
2019-10-23 22:52:05 | Edited Transcript of ALXN earnings conference call or presentation 23-Oct-19 12:00pm GMT
2019-10-23 16:03:54 | Two Drugmakers Beat Earnings Forecasts — So Why Did One Topple?
2019-10-23 12:14:00 | The Dow Scratches Out a Gain as Investors Sort Through Earnings Jumble
2019-10-23 11:26:03 | Alexion ALXN Beats on Q3 Earnings, Lifts 2019 Guidance
2019-10-23 10:10:02 | Biotech ETFs Surge on a Flurry of Positive News
2019-10-23 09:58:00 | Alexion Stock Is Rising on an Earnings Beat, Better Guidance, Buybacks
2019-10-23 09:45:01 | Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates
2019-10-23 07:55:11 | Alexion Pharmaceuticals ALXN Q3 Earnings and Revenues Top Estimates
2019-10-23 06:56:00 | Alexion Rises After Drug Developer Beats Earnings Expectations
2019-10-23 06:30:00 | Alexion Reports Third Quarter 2019 Results
2019-10-23 06:00:00 | Alexion Pharmaceuticals, Inc. to Host Earnings Call
2019-10-23 02:32:00 | Alexion Earnings, Revenue Beat in Q3
2019-10-22 11:32:03 | Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More
2019-10-22 10:18:02 | What's in Store for IDEXX Laboratories' IDXX Q3 Earnings?
2019-10-22 10:00:02 | What's in the Cards for Sarepta SRPT This Earnings Season?
2019-10-21 10:24:02 | Is Walgreens Boots WBA Likely to Disappoint in Q4 Earnings?
2019-10-21 09:33:01 | Alexion Gets FDA Approval for Label Expansion of Ultomiris
2019-10-18 20:25:08 | UPDATE 1-FDA approves Alexion's Ultomiris for another rare blood disease
2019-10-18 16:50:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.
2019-10-18 12:05:04 | Will Soliris Aid Growth for Alexion ALXN in Q3 Earnings?
2019-10-18 11:17:03 | Will Strong HIV Sales Drive Gilead's GILD Q3 Earnings?
2019-10-18 11:02:03 | What's in Store for Thermo Fisher TMO in Q3 Earnings?
2019-10-18 07:04:11 | Alexion to Buy Achillion for $930M, Strengthen PNH Franchise
2019-10-16 15:05:59 | Montco biotech firm sold for $930M, shares soar
2019-10-16 13:53:49 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Achillion Pharmaceuticals, Inc. to Alexion Pharmaceuticals, Inc. is Fair to Shareholders
2019-10-16 11:43:56 | Alexion makes $930M acquisition in bid to bolster blockbuster drug
2019-10-16 11:15:00 | Achillion Pharmaceuticals Stock Soars on Deal to Be Acquired by Alexion